Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ2 | O43526 | 1/20 | 0.38 |
| ▸ | CARM1 | Q86X55 | 5/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | PRMT5 | O14744 | 11/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | WDR77 | Q9BQA1 | 8/20 | 0.33 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.33 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17377154 | 1.00 | KCNQ2 (0.38) | KCNQ2CARM1KDM4EPRMT5MEN1 | |
| SCHEMBL17377127 | 0.89 | CARM1 (0.35) | CARM1KDM4EPRMT5MEN1KMT2A | |
| SCHEMBL17377128 | 0.89 | CARM1 (0.35) | CARM1KDM4EPRMT5MEN1KMT2A | |
| SCHEMBL17377107 | 0.78 | KDM4E (0.36) | CARM1KDM4EPRMT5MEN1KMT2A | |
| SCHEMBL17377108 | 0.78 | KDM4E (0.36) | CARM1KDM4EPRMT5MEN1KMT2A | |
| SCHEMBL17377034 | 0.73 | PRMT5 (0.54) | CARM1KDM4EPRMT5WDR77 | |
| SCHEMBL17377031 | 0.73 | PRMT5 (0.54) | CARM1KDM4EPRMT5WDR77 | |
| SCHEMBL17377044 | 0.70 | KCNQ2 (0.37) | KCNQ2KDM4E | |
| SCHEMBL17377046 | 0.70 | PRMT5 (0.49) | PRMT5WDR77 | |
| SCHEMBL17377047 | 0.70 | PRMT5 (0.49) | PRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170210751-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-07-27 | — | — | US | disclosed |
| EP-3160466-A2 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-05-03 | — | — | EP | disclosed |
| WO-2015200677-A2 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2015-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170210751-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | KCNQ2 2295/4885CARM1 8/4885KDM4E 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.